The capacity of blood (trypomastigote) forms of Trypanosoma cruzi to infect mouse peritoneal macrophages or rat heart myoblasts in vitro was inhibited by treatment 
ABSTRACT
The capacity of blood (trypomastigote) forms of Trypanosoma cruzi to infect mouse peritoneal macrophages or rat heart myoblasts in vitro was inhibited by treatment of the trypomastigotes with DL-a-difluoromethylarginine (F2Me Arg), monofluoromethylagmatine, or (E)-a-monofluoromethyl-3-4-dehydroarginine-all irreversible inhibitors of arginine decarboxylase. Similar results were obtained when F2MeArg-treated parasites were incubated with rat heart myoblasts. The inhibitory effects were characterized by marked reductions in both the proportion of infected cells and the number of parasites per 100 host cells. The concentrations of the arginine decarboxylase inhibitors that affected infectivity had no detectable effect on either the concentration or motility of the parasite and, therefore, could not have affected the collision frequency. F2MeArg appeared to inhibit the ability of T. cruzi to penetrate the host cells since the drug had no significant effect on the extent of parasite binding to the surface of the host cells. The inhibitory effect of F2MeArg was markedly reduced or abrogated in the presence of either agmatine or putrescine, as would have been expected if F2MeArg acted by inhibiting arginine decarboxylase. Addition of F2MeArg to macrophage or myoblast cultures immediately after infection or at a time when virtually all of the intracellular parasites had transformed into the multiplicative amastigote form, resulted in a markedly reduced parasite growth rate. This effect was also prevented by exogenous agmatine. These results indicate the importance of polyamines and polyamine biosynthesis in the following two important functions of T. cruzi: invasion of host cells and intracellular multiplication. Furthermore, concentrations of the inhibitors tested that affected the parasite did not alter the viability of the host cells, the cellular density of the cultures, or the ability of uninfected myoblasts to grow. Thus, arginine decarboxylase inhibitors may have a potential application in chemotherapy against T. cruzi infection.
Trypanosoma cruzi is the protozoan causing Chagas disease or American trypanosomiasis-a major health problem in South and Central America (1) . The infection is produced in most cases by trypomastigote forms borne by reduviid insects and, less frequently, by trypomastigotes contaminating blood used in transfusions (2, 3) . Mammalian host cell invasion by T. cruzi is essential for the production of disease and the continuation of the life cycle of the parasite. Establishment of this parasite in mammalian hosts requires that the invasive trypomastigotes attain a cytoplasmic localization because it is in the host cell cytoplasm that they can transform into the multiplicative amastigote form. Amastigotes divide and many eventually transform into new trypomastigotes that are released from bursting infected cells and disseminate the infection to vital tissues, including those of the heart and nervous system. Although several laboratories, including our own, have examined some of the biochemical requirements for and reactions influencing the invasion of host cells by T. cruzi (4) (5) (6) (7) (8) (9) (10) (11) (12) , our current understanding of this processwhich could underlie the development of effective chemoprophylaxis and chemotherapy-is limited. Particularly deficient is knowledge about the role of polyamines and polyamine biosynthesis in T. cruzi infectivity. Polyamines are present in a number of trypanosomatids and ornithine decarboxylase (OrnDCase), which generates putrescine from ornithine, has been shown to play an important role in the proliferation of African trypanosomes (reviewed in refs. 13, 14, and 15) . Although polyamines (e.g., putrescine, spermidine, and spermine) are present in T. cruzi trypomastigotes (P.P.M., A. J. Bitonti, F.K., and J.J.W., unpublished results), treatment with DL-a-difluoromethylornithine or other catalytic inhibitors of OrnDCase does not alter the capacity of these organisms to infect phagocytic or nonphagocytic host cells in vitro (unpublished data). It is conceivable, however, that T. cruzi relies on an alternative pathway for polyamine biosynthesis. This possibility has been explored in the present work in which we studied the effects of irreversible inhibitors of arginine decarboxylase (ArgDCase)-an enzyme heretofore identified in bacteria (16) (17) (18) (19) , plants (20) (21) (22) (23) (24) , and, apparently, in the parasitic worm Ascaris lumbricoides (25)-on T. cruzi infection.
MATERIALS AND METHODS Animals. The 6-to 9-week-old inbred CBA/J mice used to obtain resident peritoneal macrophages were purchased from The Jackson Laboratory. Four-week old Crl-CD-1(ICR)BR Swiss mice from Charles River Breeding Laboratories were used to maintain and produce blood forms of T. cruzi.
Mouse Peritoneal Macrophages. The methods used to purify unelicited mouse peritoneal macrophages and for setting up cultures ofthese cells on 3-mm diameter glass wells cut in sterile, Teflon-coated microscope slides (Cel-Line, Newfield, NJ) have been described in detail (26) . The monolayers consisted of >99% cells with typical macrophage morphology and positive staining for nonspecific esterase activity.
Rat Heart Myoblasts. Confluent monolayers of rat heart myoblasts (American Type Culture Collection, CRL 1446) were prepared on gelatin-coated microscope slide wells (see above) using Dulbecco's modified Eagle's medium (DMEM) containing penicillin at 100 units/ml and streptomycin at 100 ,ug/ml and 10% (vol/vol) heat-inactivated fetal bovine serum (GIBCO). Cell division was reduced to an insignificant level after the myoblast cultures attained confluence.
Parasites. Blood (trypomastigote) forms of Tulahuen strain T. cruzi were obtained from mice that had been infected 2 weeks previously with 2 x 105 parasites intraperitoneally.
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The trypomastigotes were purified by centrifugation over Isolymph (Gallard Schlesinger, Carle Place, NY) (27) followed by chromatography through a DEAE-cellulose column (28) . The eluted parasites were concentrated by centrifugation (800 x g, 15 min, 200C) and resuspended at 3-5 x 106 organisms per ml in the desired medium. The viability of blood-derived T. cruzi used in this work, determined by the criterion of motility, was >99.9%. The method for preparing T. cruzi amastigotes has been described in detail (29) . In all cases, parasite concentrations were determined microscopically using a hemacytometer.
Reagents. The following inhibitors of arginine decarboxylase: DL-a-difluoromethylarginine (F2MeArg) (19) , monofluoromethylagmatine(FMeAgm)and(E)-a-monofluoromethyl-3,4-dehydroarginine (FMedHArg) (30) were synthesized at the Merrell Dow Research Institute. Putrescine was purchased from Sigma. Agmatine (Aldrich) was purified by ion-exchange chromatography on Dowex-50 using a gradient from 0 to 1.5 M HCl and determined to be free of other polyamines by HPLC and thin-layer electrophoresis. Solutions of these reagents were prepared in DMEM.
Treatment of Parasites with Inhibitors of Arginine Decarboxylase. Trypomastigotes were incubated at 370C for 3-4 hr in DMEM alone or containing various concentrations of the tested inhibitors. These treatments were not extended beyond 4 hr so that the duration ofthe experiment, including the time of parasite coculture with host cells (1-2 hr), would not come too close to the time when isolated T. cruzi trypomastigotes start to show morphologic signs of transformation into other forms. The excess inhibitor was removed by washing with DMEM, and the parasite concentration was adjusted to 3-5 x 106 organisms per ml for use in experiments with macrophages or to 107 organisms per ml for use in experiments with myoblasts.
Assay of T. cruzi Interaction with Macrophages or Myoblasts. The conditions to determine T. cruzi association with macrophages or myoblasts have been described in detail (4, 5) . Briefly, cultures of macrophages or myoblasts were incubated with drug-treated or mock-treated parasites at 37°C in a 5% C02/95% air incubator for 1 hr or 2 hr. The initial parasite/cell ratio was between 3:1 and 5:1 in the various experiments with macrophages and 10:1 when myoblasts were used. The interaction was interrupted by removal of the free extracellular parasites from the cultures by three washings with DMEM and immediate fixation with absolute methanol. After staining with Giemsa, the cultures were examined microscopically (x 1000), screening not terminated by washing with DMEM, fixed with absolute methanol, and examined microscopically as described above. All assays were set up in triplicate.
Assays for Arginine Decarboxylase and OrnDCase. Purified trypomastigotes and amastigotes suspended at concentrations ranging from 107 to 6 x 109 organisms per ml in 50 mM Tris HCl (pH 7.5) containing 5 mM dithiothreitol and 1 mM EDTA were disrupted by sonication (three 1-min pulses at maximum setting; Biosonik III, Bronwill, NY). The presence of arginine decarboxylase or OrnDCase activity in these materials was tested by a modification (19) (Table 1) . Although the extent of the observed reduction varied among repeat experiments (data not shown), the effect itself was highly reproducible and always statistically significant. In the various repeat experiments the minimal concentration of F2MeArg causing significant inhibition was 10 mM (data not shown) to 12.5 mM (Table 1) whereas only 3 mM FMeAgm or FMedHArg was required to produce significant inhibition. Neither suspensions of trypomastigotes nor cultures of macrophages or myoblasts denoted any significant loss in cell viability after incubation with the tested concentrations of F2MeArg, FMeAgm, and FMedHArg for 3-4 hr at 37°C. Furthermore, there was no detectable change in parasite motility or concentration after these treatments (data not shown). Since our supply of FMeAgm and FMedHArg was limited, we used F2MeArg in all subsequent experiments.
The reduced level of parasite-macrophage interaction due to parasite treatment with arginine decarboxylase inhibitors might have resulted from impaired parasite binding to macrophages or a diminution of its membrane-penetrating capacity. To explore the first possibility, we carried out parallel assays at 37°C (a temperature at which both binding and penetration can occur) and at 40C [only surface binding occurs at this temperature (31)]. As can be seen in Table 2 , the extent of parasite-macrophage association was significantly reduced by F2MeArg pretreatment of T. cruzi when the cocultures were incubated at 370C; the extent ofparasite-macrophage interaction was minimal at 4°C and was not visibly affected. The second possibility was examined in experiments in which F2MeArg-treated T. cruzi were cocultured with myoblasts. Since these cells are not phagocytic, parasite interiorization results exclusively from membrane penetration. The results presented in Table 3 showed that concentrations of F2MeArg similar to those effectively reducing parasite-macrophage interaction also affected the capacity of the trypanosomes to infect the myoblasts.
The observed reduction in T. cruzi infectivity caused by F2MeArg might have been due to an accumulation of arginine owing to putative inhibition of arginine decarboxylase or to the presence of F2MeArg, an arginine analogue. To test this possibility we measured the level of interaction between T. cruzi and macrophages after pretreating the flagellates with DMEM containing or lacking concentrations of DL-arginine ranging from 0.5 mM to 50 mM. Both the percentages of infected macrophages and the average numbers of trypanosomes per 100 macrophages obtained with DL-argininetreated and mock-treated parasites were comparable (data not shown).
If F2MeArg reduced T. cruzi infectivity by inactivating arginine decarboxylase, the effect should be prevented by agmatine, the product of arginine decarboxylation. As can be seen in Table 4 , this was indeed the case. Similar results were obtained when putrescine, the product of metabolic conversion of agmatine, was present during the F2MeArg treatment.
Although the bond between F2MeArg and arginine decarboxylase is covalent and causes irreversible inactivation of the enzyme (19) , the inhibitory effects of F2MeArg started to subside 1 hr after the treatment and were virtually undetectable after 2 hr (Table 5) . In these assays, the experimental results were compared with those of parallel controls in which we used parasites that had been incubated with medium alone instead of the F2MeArg solution and were then incubated in fresh medium for the same lengths of time. This was necessary to take into account the time-dependent increases in parasite infectivity that occur when recently isolated trypomastigotes are maintained in cell-free medium for a few hours (33) . Effects of F2MeArg on Intracellular Growth of T. cruzi. We also tested whether F2MeArg would interfere with the intracellular replication of T. cruzi. This was done by adding the agent to cultures of macrophages and myoblasts that had already been infected by the trypomastigotes. The parasite loads of the host cells were determined at 24-hr intervals for a 2-day (myoblasts) or 4-day (macrophages) period, starting immediately after the addition of F2MeArg. As can be seen in Fig. 1 , parasite counts were significantly lower in the F2MeArg-treated cells than in the mock-treated controls. Similar inhibition was seen when 30 or 50 mM F2MeArg was added to the cultures 12 hr (myoblasts) and 24 hr (macrophages) after removal of the free trypomastigotes, i.e., after all intracellular organisms had transformed into amastigotes, and parasite loads were determined 24 hr later (data not shown). In this type of experiment we also tested the effect of 0.3 mM agmatine during the F2MeArg treatment and found the inhibitory effect to be either not detectable or significantly reduced (data not shown).
We used confluent myoblast monolayers in our experiments because cell division is brought to a virtual halt under these conditions and could not artifactually reduce the number of parasites per 100 cells over time. However, we wanted to know if the F2MeArg treatment would have a toxic action affecting myoblast growth in younger cultures. There was no difference in the rate of growth of myoblasts treated with up to 50 mM F2MeArg compared to that of cells incubated in medium alone (data not shown).
Arginine decarboxylase and OrnDCase activity could not be detected in samples containing up to 2.4 x 109 trypomastigotes and 2 x 107 amastigotes by measuring the release of
[14C]02 from [1-14C] arginine (for arginine decarboxylase activity) and [1-14C] ornithine (for OrnDCase activity) (19, 30, 32 ) (data not shown). These methods readily detect arginine decarboxylase activity in Escherichia coli, Pseudomonas aeruginosa (19) , and plants (34) and OrnDCase activity in E.
coli (30) , African trypanqpmes (15) , and plants (34). .9) 44.3 ± 3.2 (29.9) The trypomastigotes were pretreated as indicated (at 37°C for 3 hr), washed, and then cocultured with untreated macrophages for 1 hr. Only the differences between the values obtained with parasites treated with F2MeArg alone and the corresponding control values (DMEM) were statistically significant (P < 0.05). Values in parentheses are the percent change.
DISCUSSION
The reduced infective capacity of T. cruzi trypomastigotes after pretreatment with three different catalytic inhibitors of arginine decarboxylase suggested the presence of this enzyme and a role for it in host cell invasion. The lack of effect of parasite pretreatment with DL-arginine rendered unlikely the possibility that F2MeArg acted by increasing the intracellular level of arginine or that F2MeArg was itself acting by some other "arginine-analog" effect, and pointed to arginine decarboxylase inhibition as a more probable mechanism. The fact that exogenous agmatine prevented the inhibitory effect of F2MeArg when it was present during parasite drug pretreatment further supported this possibility since agmatine can be derived metabolically only from arginine decarboxylation (17) . Exogenous putrescine also prevented the F2MeArg effect, suggesting that, in T. cruzi, this polyamine has agmatine as a precursor, as is the case in bacteria and plants (17) .
Parasite pretreatment with F2MeArg also inhibited their interaction with myoblasts (to which the parasite can gain access only by membrane penetration). This infers that arginine decarboxylase inhibitors affected mostly the capacity of the parasite to penetrate host cells and suggests that infection of both cell types relies on a common biochemical mechanism involving polyamine biosynthesis.
The F2MeArg effect was seen when parasites and macrophages were cocultured at 37°C whereas at 4°C the interaction was minimal and was not visibly affected by F2MeArg pretreatment of the parasites. Thus, it would appear that at least the membrane-penetrating capacity of the flagellate was seriously compromised by F2MeArg. The low degree of parasite-macrophage interaction observed at 4°C suggested reminiscent of the rapid turnover of OrnDCase in other trypanosomatids where this enzyme plays a key role in polyamine production (14) .
Treatment of T. cruzi trypomastigotes with OrnDCase inhibitors under conditions similar to those used in the present study did not affect significantly their capacity to infect murine macrophages (unpublished data). In contrast, all three arginine decarboxylase inhibitors used in the present study curtailed infection, and such effect by F2MeArg was prevented by agmatine. This suggested that the parasite utilizes arginine decarboxylase to synthesize polyamines and that ongoing polyamine biosynthesis plays an important role in infectivity. This would be a distinctive feature of T. cruzi because, outside of bacteria (16) (17) (18) (19) and higher plants (24, 34) , arginine decarboxylase has apparently only been found in the intestinal parasitic worm A. lumbricoides (25) . However, by the method of Wu and Morris (32), we have been unable to detect active arginine decarboxylase in trypomastigotes and amastigotes of T. cruzi despite using relatively large numbers of these parasites. Nevertheless, the enzyme might be present in the parasite in an inactive state and become activated after the organism engages a host cell or might only be genetically expressed after contacting the host cell surface. Alternatively, arginine decarboxylase may become inactivated during parasite sonication. At present, we cannot rule out that the tested inhibitors might have affected an as yet undisclosed mechanism not involving arginine decarboxylase. However, the prevention of the F2MeArg effects by putrescine and particularly by agmatine would seem to argue against the latter possibility.
Since polyamines play an important role in cellular proliferation (35, 36) , impairment of intracellular parasite growth by F2MeArg is likely to be accompanied by inhibited polyamine biosynthesis. This impairment was also prevented by exogenous agmatine, pointing to arginine decarboxylase inhibition as the relevant mechanism. However, in the absence of direct evidence for the presence of arginine decarboxylase in T. cruzi, an alternative mechanism cannot be ruled out.
T. cruzi, as well as the African trypanosome Trypanosoma brucei brucei and Leishmania mexicana, has also been reported to contain trypanothione, a spermidine-containing glutathione reductase cofactor (37) . Thus, reduction of spermidine biosynthesis by restriction of putrescine via inhibition of arginine decarboxylase most likely would lower the amount of this required cofactor in the parasite. Such a mechanism could affect vital functions of T. cruzi, including infectivity and intracellular multiplication.
The absence of arginine decarboxylase in mammalian cells would present this enzyme as a selective target for chemotherapy for T. cruzi infection. Whether or not future research supports this hope, the identification of a biochemical event affecting two of the most important biological functions of T. cruzi is in itself an exciting new development deserving further attention.
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